Cost-effectiveness as a guide to pricing a new pharmaceutical product

Area of Science:

• Health economics
• Clinical innovation
• Pharmaceutical pricing

Background:

• Assessing the economic value of new medicines is crucial for healthcare decision-making.
• Clinical innovations require rigorous economic evaluation before market entry.
• Pharmaceutical pricing strategies impact both accessibility and healthcare budgets.

Purpose of the Study:

• To conduct a cost-effectiveness analysis of a significant clinical innovation.
• To determine if a premium drug price is justifiable based on potential cost savings.
• To evaluate the feasibility and informativeness of pre-price economic assessments for new medications.

Main Methods:

• Utilized a structured survey of professional judgments to estimate research costs.
• Applied cost-effectiveness analysis (CEA) to a novel pharmaceutical product.
• Conducted sensitivity analyses using varied cost assumptions and effectiveness definitions.

Main Results:

• The analysis suggests a premium price for the drug is economically justified due to substantial cost savings.
• Results remained robust despite variations in cost assumptions and definitions of effectiveness.
• Ex ante economic evaluation proved feasible and provided valuable insights prior to price setting.

Conclusions:

• Economic evaluations conducted before drug pricing can be both practical and insightful.
• A premium drug price can be justified if it leads to significant overall cost savings.
• Cost-effectiveness analysis is a vital tool for evaluating new medicines and informing pricing decisions.